AstraZeneca’s AZD3152 Study: Promising Update on COVID-19 Prophylaxis

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca recently completed a Phase II study titled ‘A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)’. The study aimed to assess the safety and efficacy of AZD3152 in adults at high risk of severe COVID-19 due to compromised immune responses post-vaccination.

Intervention/Treatment: The intervention tested was AZD3152, a monoclonal antibody (mAb) designed to provide broad neutralizing activity against various SARS-CoV-2 variants. It was administered as a single 300 mg intramuscular dose, compared to a placebo.

Study Design: This interventional study was randomized and double-blind, involving 116 participants in Russia. Participants were allocated in a 3:1 ratio to receive either AZD3152 or a placebo. The study employed a parallel intervention model with quadruple masking, aiming primarily at prevention.

Study Timeline: The study began on September 29, 2023, with primary completion expected by April 30, 2025. The last update was submitted on August 14, 2025. These dates are crucial as they mark the progression and reporting of the study’s findings.

Market Implications: The completion of this study could positively impact AstraZeneca’s stock performance by reinforcing its position in the COVID-19 prophylactic treatment market. With ongoing competition in the pharmaceutical industry, successful results could enhance investor confidence and market share.

The study is ongoing, with further details available on the ClinicalTrials portal.